Real-world Cohort Study of Antiretroviral Therapy in HIV Patients With Opportunistic Infections
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorShanghai Public Health Clinical Center
About this trial
This study stratified and compared the differences in virological efficacy and sustained viral suppression status between HIV-infected patients with and without opportunistic infections, providing a basis for optimizing antiretroviral therapy for opportunistic infections and a data foundation for establishing predictive models.
Eligibility criteria
Qualifiers
For the opportunistic infection treatment group: Inclusion criteria: a) Age ≥ 18 years, diagnosed with HIV-1 infection; b) Clinically diagnosed with one of the following opportunistic infections and initiating anti-infective therapy: PCP, tuberculosis, NTM infection, CMV infection, herpes simplex virus and varicella-zoster virus infection, toxoplasmosis encephalopathy, oral fungal infection, cryptococcal meningitis, Marneffei basket disease, PML; c) Intending to initiate ART therapy or currently receiving ART therapy; d) The individual (or their legal representative) voluntarily signs a written informed consent form.
For the non-opportunistic infection group: a) Age ≥ 18 years, diagnosed with HIV-1 infection; b) Intending to start ART treatment or currently receiving ART treatment; c) The individual (or legal representative) voluntarily signs a written informed consent form.
Disqualifiers
For the opportunistic infection treatment group: Exclusion criteria: a) Individuals suffering from major neurological or psychiatric illnesses such as schizophrenia, epilepsy, or severe depression; b) Individuals with a history of drug use or recent history of alcohol or drug dependence; c) Individuals deemed unsuitable for participation by researchers, such as those in the acute phase of severe cardiovascular disease; d) Individuals deemed unsuitable for participation by other researchers; e) Individuals whose long-term follow-up requirements and frequency cannot be guaranteed.
For the non-opportunistic infection group: a) Individuals with coexisting opportunistic infections; b) Individuals suffering from major neurological or psychiatric illnesses such as schizophrenia, epilepsy, or severe depression; c) Individuals with a history of drug use or recent history of alcohol or drug dependence; d) Individuals deemed unsuitable for participation by researchers, such as those in the acute phase of severe cardiovascular disease; e) Individuals deemed unsuitable for participation by other researchers; f) Individuals whose long-term follow-up requirements and frequency cannot be guaranteed.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
8,000 Participants
are grouped into 2 trial groupsLocations
Sponsors and collaborators
Shanghai Public Health Clinical Center
Lead sponsor
Chest Hospital of Guangxi Zhuang Autonomous Region
Collaborator
Beijing Ditan Hospital
Collaborator
Guangzhou Eighth People's Hospital, Guangzhou Medical University.
Collaborator
The Second Hospital of Nanjing Medical University
Collaborator
Chongqing Public Health Medical Treatment Center
Collaborator
GuiYang Public Health Clinical centre
Collaborator
Chengdu Public Health Clinical Center
Collaborator
The Third People's Hospital of Yunnan Province
Collaborator
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Collaborator
Beijing YouAn Hospital
Collaborator
Peking Union Medical College Hospital
Collaborator
Zhejiang University
Collaborator
Source ClinicalTrials.gov